TransThera Sciences (Nanjing), Inc. (HKG:2617)

Market Cap	3.32B -96.4%
Revenue (ttm)	40.93M
Net Income	-310.05M
EPS	-0.78
Shares Out	407.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,133,500
Open	8.26
Previous Close	8.28
Day's Range	8.06 - 8.27
52-Week Range	7.53 - 236.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 132
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2617

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error